Loss of a Single Splicing Protein Reshapes the Heart’s Scarring Response

A single RNA-binding protein, best known for its role in deciding which versions of genes get made, appears to sit at a controlling point in the molecular machinery that drives fibrosis after cardiac injury. In a study published in Nature Communications, researchers report that deleting the gene encoding PTBP1 specifically in cardiac fibroblasts changes how these scar-forming cells respond to profibrotic signals, with the effect traced to widespread shifts in alternative splicing. The finding reframes fibrosis not simply as a matter of which genes are switched on, but of how their RNA transcripts are cut and pasted into mature messages.

Cardiac fibrosis is the pathological accumulation of extracellular matrix proteins in the heart, a process orchestrated primarily by fibroblasts. When the heart is stressed by pressure overload, myocardial infarction, or chronic inflammation, quiescent fibroblasts activate into myofibroblasts, cells that proliferate, migrate, contract, and deposit large quantities of collagen and other matrix components. In the short term this response is protective, patching damaged tissue and preserving the structural integrity of the ventricular wall. When the signal never shuts off, however, the accumulating scar stiffens the myocardium, impairs electrical conduction, and gradually pushes the heart toward diastolic dysfunction and heart failure. Clinically, no approved therapy directly targets this process; existing treatments manage hemodynamic load and neurohormonal activation while fibrosis progresses.

PTBP1, polypyrimidine tract binding protein 1, is one of the cell’s most influential splicing factors. Alternative splicing allows a single gene to yield multiple protein isoforms by including or excluding different RNA segments, and PTBP1 binds specific sequence motifs on precursor messenger RNA to tip these decisions. Beyond splicing, PTBP1 participates in RNA stability, translation, and even transcript localization, and it is famous in regenerative biology for its ability, when silenced, to help convert non-neuronal cells into neuron-like cells. Its role in the heart’s fibrotic armory, however, has been far less clear, and the new study set out to test whether fibroblast PTBP1 is a bystander or an active participant in scarring.

To resolve that question, the investigators generated mice in which PTBP1 was deleted selectively in cardiac fibroblasts, sidestepping the developmental and neuronal roles of the protein that complicate whole-animal knockout approaches. This cell-type-specific strategy is essential because PTBP1 is broadly expressed; removing it everywhere would produce a tangle of secondary effects impossible to attribute to fibroblasts. With the deletion restricted to the scar-forming population, the researchers could ask a clean question: when fibroblasts lose their master splicing regulator, does the fibrotic response to cardiac stress change, and if so, how?

The answer was yes, and the mechanism was legible at the level of the transcriptome. Fibroblasts lacking PTBP1 showed broad alterations in alternative splicing, and among the affected transcripts were genes central to the profibrotic program. The splice isoforms produced in the knockout cells differed from those made in wild-type fibroblasts in ways that modulated the cells’ sensitivity to the cytokine TGF-beta, the dominant driver of myofibroblast differentiation, and to the downstream signaling that activates collagen production and contractility. In effect, removing the splicing factor rewired the interpretive layer between the fibrotic signals a cell receives and the proteins it deploys in response.

This outcome matters conceptually because much of fibrosis research has concentrated on transcriptional control, asking which transcription factors activate fibrotic genes and which signaling cascades converge on their promoters. The PTBP1 data demonstrate that post-transcriptional regulation constitutes a second, largely independent control layer. A gene can be transcribed at a normal rate yet produce a protein with altered function if its exons are assembled differently. In fibroblasts, that assembly step is influenced heavily by PTBP1, meaning the intensity and character of the scarring response can be tuned without changing gene expression in the conventional sense.

Technically, the study illustrates the current standard toolkit for dissecting splicing in vivo. RNA sequencing of fibroblasts isolated from control and knockout animals allowed the team to quantify splicing changes genome-wide, identifying skipped exons, alternative splice sites, and shifted isoform ratios across thousands of transcripts. These molecular maps were then connected to cellular phenotypes measured in culture and to the intact organ in models of cardiac stress, an approach that links a molecular event, exon usage, all the way through to tissue-level consequences. It is exactly this chain of evidence, from factor to isoform to cell behavior to organ pathology, that turns a correlation into a credible regulatory mechanism.

One of the most interesting implications concerns isoform switching as a therapeutic concept. If individual fibrotic genes exist in profibrotic and less-pathological isoforms, then future interventions might not need to silence a gene outright, which is often toxic because genes rarely have a single role. Instead, drugs could be designed to nudge splicing decisions toward protective isoforms. Splice-switching oligonucleotides, short synthetic molecules that bind pre-mRNA and redirect the splicing machinery, are already approved for neuromuscular disease and are being explored in cardiology. A validated role for PTBP1 in the fibrotic response provides a concrete molecular handle for that class of strategy in heart disease.

The work also adds to a growing literature on RNA-binding proteins as disease genes. Over the past decade, RNA processing factors have been implicated in cardiomyopathy, congenital heart disease, and cardiac aging, but fibroblasts have received less attention than cardiomyocytes in this respect. Given that fibroblasts compose the majority of non-muscle cells in the heart and are the chief effectors of remodeling, the demonstration that a single splicing factor modulates their pathological activation suggests that the post-transcriptional biology of these cells is a rich and underexplored therapeutic landscape.

Important caveats remain. PTBP1 is a pleiotropic regulator, and changing its dosage in fibroblasts will inevitably affect many targets, some beneficial and some not; translating the finding into a therapy will require identifying the specific isoform switches that carry the antifibrotic effect and finding selective ways to control them. Dose, timing, and cell-type specificity will all need careful optimization, and the long-term consequences of altering fibroblast splicing in a chronically stressed heart are unknown. Nevertheless, the study delivers a clear and consequential message: the heart’s scarring response is governed not only by which profibrotic genes are expressed, but by how their RNA is edited, and a single RNA-binding protein helps call those shots. In a field where therapeutic options for fibrosis remain limited, that is a lead worth pursuing.

Subject of Research: Role of the splicing factor PTBP1 in cardiac fibroblast profibrotic activation and alternative splicing.

Article Title: Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing

Article References: Ricketts, S. N., Farber, G. M., Verma, S. K., Dong, Y., Xie, Y., Takasugi, P. R., Chen, S., Du, L., Wang, H., Hui, W., Keles, C., Tsoy, S., Fuller, G., Wang, M., Gentile, G. M., Giudice, J., Kuyumcu-Martinez, M. N., Liu, J., & Qian, L. (2026). Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing. Nature Communications. https://doi.org/10.1038/s41467-026-77609-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77609-7

Keywords: PTBP1, cardiac fibroblasts, alternative splicing, cardiac fibrosis, TGF-beta, RNA-binding protein, myofibroblast, heart failure, splicing factors, extracellular matrix, Cardiac, fibroblast